A second international co-operative investigation into thiacetazone side-effects Rashes on two thiacetazone containing regimens

Ferguson, Gordon; Nunn, Andrew; Fox, Wallace; Miller, Arnold; Robinson, Donna; Tall, Ruth

doi:10.1016/0041-3879(71)90040-7

Cited by 21 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before the onset of the AIDS epidemic, numerous cases of SJS were reported. 144,145 During the AIDS era, reports of cutaneous reactions to INH have increased significantly. Gordin and colleagues recently observed severe (grade 4 or 5) rashes secondary to INH use in 0.6% of 792 HIV-infected patients.…”

Section: Isoniazidmentioning

confidence: 99%

Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection

Miller¹,

Warshaw²

2007

Dermatitis

View full text Add to dashboard Cite

Adverse reactions to medication are significant contributors to morbidity and mortality in patients with human immunodeficiency virus (HIV) infection. Cutaneous events not only constitute a significant portion of these reactions, they may also herald developing systemic reactions such as hemato-, nephro-, and hepatotoxicity. The identification of cutaneous adverse reactions and drug culprits and the proper management of reactions are of paramount importance for these patients. This review focuses specifically on adverse cutaneous reactions to antimicrobials that are commonly used in the management of patients with HIV infection.

show abstract

Section: Isoniazidmentioning

confidence: 99%

Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection

Miller¹,

Warshaw²

2007

Dermatitis

View full text Add to dashboard Cite

show abstract

“…It is recognized that patients of different ethnic origins may respond and react differently to the same therapeutic agent, as illustrated by the examples of thiacetazone, isoniazid, beta-blockers and angiotensin-converting enzyme inhibitors [28][29][30][31][32][33]. So the results of clinical trials in Europe and North America may not be directly applicable to Asian populations, and well-conducted clinical trials are needed to evaluate the safety and efficacy of new therapeutic agents in these populations.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Cefpirome in Comparison with Ceftazidime in Chinese Patients with Sepsis due to Bacterial Infections

Fang

Chen²,

Lin³

et al. 2000

Chemotherapy

View full text Add to dashboard Cite

Background: The safety and efficacy of cefpirome (CPM), a fourth-generation cephalosporin, has not yet been studied in an Asian population. Methods: Sixty-nine adult Chinese patients with sepsis due to bacterial infections were enrolled in the study and randomly assigned to receive CPM (2 g i.v. every 12 h) or ceftazidime (2 g i.v. every 8 h). Results: Both groups were comparable in terms of demographic, clinical and microbiological features. The causative pathogen was Escherichia coli or Klebsiella pneumoniae in the majority of microbiologically documented cases. The rates of clinical response (94 vs. 94%) and bacteriological response (65 vs. 68%) were similar in both groups. Similar adverse events, including rashes, gastrointestinal upset and asymptomatic elevation of hepatic enzymes, occurred in a minority of patients in both groups. All events were self-limited after discontinuation of the drugs. Conclusion: CPM is as safe and effective as ceftazidime in the treatment of sepsis due to bacterial infections in Chinese patients.

show abstract

“…Nevirapine has been reported to cause severe diffuse erythematous rash that may progress to TEN. Thiacetazone used in the treatment of HIV seropositive tuberculosis patients may cause skin reactions in 4% to 18% of the patients [57].…”

Section: Cutaneous Drug Eruptions In Hiv/aids Patientsmentioning

confidence: 99%

Management of cutaneous drug reactions

Babu

Belgi

2002

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Drugs are potent chemicals that often have effects in the body beyond the desired action. These effects may range from mild and expected side effects to dramatic and life-threatening anaphylaxis. Adverse drug reactions account for between 2% and 6% of hospital admissions and may prevent administration of otherwise effective therapeutic agents. Cutaneous and mucocutaneous eruptions are the most common adverse reactions to oral or parenteral drug therapy, and the spectrum ranges from transitory exanthematous rash to the potentially fatal toxic epidermal necrolysis. Different mechanisms, including both immunologic and nonimmunologic, are responsible for cutaneous adverse drug reaction. The treatment of cutaneous drug eruptions essentially rests on accurate history, a thorough physical examination, discontinuation of the offending drug, and supportive care. The management of a cutaneous drug eruption is very much individualized, based on the clinical setting. This review aims to provide a general approach to the patient with a presumed cutaneous drug reaction.

show abstract

A second international co-operative investigation into thiacetazone side-effects Rashes on two thiacetazone containing regimens

Cited by 21 publications

References 8 publications

Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection

Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection

Safety and Efficacy of Cefpirome in Comparison with Ceftazidime in Chinese Patients with Sepsis due to Bacterial Infections

Management of cutaneous drug reactions

Contact Info

Product

Resources

About